Discussion and development of standards for appropriate monitoring led
to the following key recommendations for ordering, sampling, and anal
yzing antiepileptic drugs: Monitoring should usually be done on trough
specimens after steady-state has been reached and always with an appr
opriate medical indication; nonsteady-state concentrations may be indi
cated in selected situations. Monitoring of free phenytoin and free va
lproic acid is indicated in specific situations and should be done in
serum. The metabolite of primidone, phenobarbital, should be measured
concurrently with parent drug, but the active metabolite of carbamazep
ine does not need to be monitored unless the patient is exhibiting an
unusual toxic response that cannot be otherwise explained. Assays used
for antiepileptic drug monitoring should display a long-term CV of <1
0% and preferably <5%. Subtherapeutic and supratherapeutic drug concen
trations should be investigated on a regular basis as part of a qualit
y assurance process.